| ipi + gp100 vs gp100 | No demonstrated result suggested death (overall survival) by 31% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | 0.69 [0.56 0.85] | p=0.04 | 0 | 539 | 1 | Hodi (ipi + gp100), | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| ipilimumab vs placebo | recurrence free survival by 24% (fully demonstrated) Grade 3–5 drug-related AEs by 107% (harmful effect) suggested distant metastasis free survival by 24% (not demonstrated) suggested death (overall survival) by 28% (not demonstrated) suggested progression or death (progression free survival PFS) by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| recurrence free survival | 0.76 [0.64 0.90] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | distant metastasis free survival | 0.76 [0.63 0.91] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | death (overall survival) | 0.72 [0.58 0.89] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | progression or death (progression free survival PFS) | 0.76 [0.64 0.90] | p=0.04 | 0 | 951 | 1 | EORTC 18071 (Eggermont), | | Grade 3–5 drug-related AEs | 2.07 [1.57 2.72] | p=0.04 | 0 | 945 | 1 | EORTC 18071 (Eggermont), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| ipilimumab + dacarbazine vs dacarbazine | death (overall survival) by 28% (fully demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | 0.72 [0.59 0.87] | p=0.04 | 0 | -18 | 1 | Robert, | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| ipilimumab 3 mg/kg vs gp100 | No demonstrated result suggested death (overall survival) by 36% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| recurrence free survival | no data | | distant metastasis free survival | no data | | death (overall survival) | 0.64 [0.49 0.84] | p=0.04 | 0 | 273 | 1 | Hodi (ipi alone), | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
